Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Sanofi SA (NASDAQ:SNY) presented data from two Phase 3 studies of fitusiran for the prophylactic treatment with hemophilia A or B, with or without inhibitors.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
- Data were shared at the American Society of Hematology (ASH) Annual Meeting.
- Fitusiran, an RNAi drug designed to silence the gene that overproduces a protein responsible for clotting suppression.
- Fitusiran cut patients’ annualized bleeding rate (ARB) rate by 89% over control, demonstrating prophylactic for bleeding episodes as a once-monthly injection.
- In this Phase 3 study, dubbed ATLAS-A/B, 50.6% of patients treated with fitusiran had zero treated bleeds during the study compared with just 5% of patients in the on-demand arm.
- Sanofi revealed safety data from ATLAS-A/B with 19% of patients in the fitusiran arm reporting abnormally high levels of ALT and AST proteins. Meanwhile, there were no reported cases of thrombosis.
- Sanofi reported updated results from ATLAS-INH showing 24.4% of patients in the study had abnormally high levels of ALT/AST, and two patients presented suspected or confirmed thrombosis.
- Price Action: SNY shares are down 1.05% at $48.26 during the market session on the last check Tuesday.
- Check out our coverage of the American Society of Hematology (ASH) Annual Meeting 2021 here.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.